

CYP19A1 single nucleotide polymorphism associations with *CYP19A1*, *NFκB1*, and *IL6* gene expression in human normal colon and normal liver samples

Rosalind B Penney¹
 Abbie Lundgreen²
 Aiwei Yao-Borengasser³
 Vineetha K Edavana³
 Suzanne Williams³
 Ishwori Dhakal⁴
 Roger K Wolff²
 Susan Kadlubar³
 Martha L Slaterry²

¹Department of Environmental and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, AR, ²Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT, ³Division of Medical Genetics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Background: Estrogen is known to decrease the risk of colon cancer in postmenopausal women, and may exert its actions by decreasing interleukin-6 (IL6) production via stabilization of the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB). Estrogens are biosynthesized by *CYP19A1* (aromatase), so it is possible that genetic variations in *CYP19A1* influences the risk of colon cancer by altering expression of *CYP19A1*. Further, studies on gene-gene interactions suggest that single nucleotide polymorphisms in one gene may affect expression of other genes. The current study aims to explore the role of *CYP19A1* single nucleotide polymorphisms on *CYP19A1*, *NFκB1* and *IL6* gene expression.

Methods: Phenotype-genotype associations, cross-associations between genes, and haplotype analyses were performed in both normal human colon (n=82) and liver (n=238) samples.

Results: *CYP19A1* rs10459592, rs1961177, and rs6493497 were associated with *CYP19A1* expression in colon samples ($P=0.042$, $P=0.041$, and $P=0.013$, respectively). *CYP19A1* single nucleotide polymorphisms (rs12908960, rs730154, rs8025191, and rs17523880) were correlated with *NFκB1* expression ($P=0.047$, $P=0.04$, $P=0.05$, and $P=0.03$, respectively), and *CYP19A1* rs11856927, rs2470152, and rs2470144 ($P=0.049$, $P=0.025$, $P=0.047$, respectively) were associated with *IL6* expression in the colon. While rs730154 and rs17523880 could not be analyzed in the liver samples, none of the other associations with the colon were replicated in the liver samples. Haplotype analysis revealed three separate haplotypes of the *CYP19A1* single nucleotide polymorphism that were significantly associated with *CYP19A1*, *NFκB1*, and *IL6* gene expression.

Conclusion: *CYP19A1* single nucleotide polymorphisms are associated not only with *CYP19A1* expression but also with *NFκB1* and *IL6* expression. These data demonstrate the possible functional consequences of genetic variation within the *CYP19A1* gene on other genes in a biologically plausible pathway.

Keywords: *CYP19A1*, *NFκB1*, interleukin-6, single nucleotide polymorphism, colon, liver

Introduction

Colorectal cancer is the third most common cancer and cause of cancer death in women.¹ The link between estrogen and the risk of colon cancer has been well established.²⁻⁴ Hormone replacement therapy has been shown to decrease the risk of colon cancer in postmenopausal women,⁵ with two separate meta-analyses demonstrating a 20% decrease in risk of colon cancer in ever users.^{6,7}

One mechanism by which estrogen exerts its protective action may be via modulation of the immune system response.⁸ A recent study in mice indicated that estrogen suppresses

Correspondence: Susan Kadlubar
 University of Arkansas for Medical Sciences, 4301 W Markham, #580,
 Little Rock, AR 72205, USA
 Tel +1 501 526 7957
 Email sakadlubar@uams.edu

inflammation-associated colon cancer, even after initiation of colonic DNA damage by administration of azoxymethane and dextran sulfate sodium.⁹ Specifically, estradiol negatively regulates the inflammatory cytokine, interleukin-6 (IL6).^{10,11} It has been demonstrated that IL6 levels increase as Duke's stage increases in patients with colorectal cancer, so increased IL6 expression may play a role in the risk of colon cancer.¹² CYP19A1 (aromatase), which facilitates the biosynthesis of estrogens, is expressed by colorectal adenocarcinoma cell lines,¹³ and colon carcinoma has increased expression of CYP19A1 mRNA relative to non-neoplastic colon mucosa.¹⁴ While the mechanisms of this difference in expression have not been identified, it has been postulated that an inflammatory response process may be involved, with expression of IL6 and CYP19A1 activity having been positively correlated in macrophage-rich tissue¹⁵ and IL6 and other inflammatory cytokines having been shown to increase the expression of CYP19A1. This increases local estrogen levels,¹⁶ which can inhibit binding of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) to inflammatory gene promoters.¹⁷ NFκB is a transcription factor that has binding sites in or near many cytokine promoter regions,¹⁸ and is closely associated with the development of cancer, angiogenesis, invasion, and metastasis.¹⁹ NFκB is known to mediate the synthesis of IL6,²⁰ indicating a possible feedback loop.

Single nucleotide polymorphisms (SNPs) in *CYP19A1* have been linked to a risk of colon cancer.^{21–23} Interactions between SNPs in pairs of genes, such as *CYP19A1* and *NFκB1*, have also been shown to affect the risk of colon cancer.²² The functionality of these associations, as determined by gene expression, has not been explored. The primary purpose of this study was to validate findings from a large case-control study²² by exploring the gene expression functionality of (and possible interactions between) SNPs in *CYP19A1* and gene expression of CYP19A1, NFκB1, and IL6 in normal colon samples. Haplotype analysis of multiple *CYP19A1* SNPs was performed to understand better the broader variation in the *CYP19A1* gene and how it may influence expression.

Materials and methods

Tissue samples

Deidentified normal frozen colon and liver tissue samples were obtained from the Cooperative Human Tissue Network and stored at -80°C . For colon tissues ($n=82$), 54% were from male patients and 46% were from female patients. The mean patient age was 60.48 (range 17–92) years, and the samples were from patients of Caucasian ($n=51$), African American ($n=23$), Asian ($n=1$), or unknown ($n=7$) origin.

For the liver samples ($n=238$), the mean patient age was 58.79 (range 1–102) years, and the samples were from patients of Caucasian ($n=195$), African American ($n=21$), Hispanic ($n=2$), or other/unknown ($n=20$) origin. Fifty-three percent of the liver samples came from male patients, 45% from female patients, and 2% from patients of unknown sex.

Reverse transcription and quantitative real-time PCR

To increase the yield in normal colon tissue samples, total RNA was isolated utilizing Trizol reagent (Invitrogen, Grand Island, NY, USA) for homogenization, and the RNEasy Mini kit (Qiagen, Valencia, CA, USA) for isolation using a protocol developed by Mauricio Rodriguez-Lanetty (unpublished) but with minor alterations. Briefly, tissue samples (~25 mg) were homogenized in 150 μL of Trizol using a Bullet Blender (Next Advance, Averill Park, NY, USA) and stainless steel beads. The homogenate was placed in a new vial with 450 μL of Trizol. After adding 100 μL of chloroform, the vials were shaken, incubated for 2 minutes at room temperature, and centrifuged, after which the supernatant was placed in a new vial. An equal portion of 100% ethanol was added, and the mixture was placed in an RNEasy spin column. The RNA was washed and eluted according to the RNEasy protocol. Total DNA was isolated from normal colon samples and total RNA and DNA were isolated from normal liver tissue samples using the AllPrep DNA/RNA/Protein mini kit (Qiagen).

First strand cDNA synthesis was performed using a High Capacity RNA-to-cDNA Kit (ABI, Carlsbad, CA, USA) on 500 ng of total RNA as measured by an RNA 6000 Nano kit (Agilent, Santa Clara, CA, USA). Quantitative real-time PCR reactions were performed on a 7900HT Fast Real-Time PCR System (ABI) using Taqman primer/probe sets and Taqman Fast Universal PCR Master Mix no AmpErase[®] UNG (ABI). Experiments were run as per the manufacturer's protocol (except as noted) in quadruplicate on CYP19A1 colon cDNA and in triplicate on NFκB1 and IL6 cDNA and CYP19A1 liver cDNA diluted 1:10 for 50 PCR cycles. Samples were normalized to β -actin, discarding those with β -actin cycle thresholds (Cts) that were >30 ($n=12$ for colon CYP19A1 analysis, $n=5$ for colon IL6 analysis, $n=4$ for colon NFκB1 analysis; and $n=8$ for all liver analyses). Gene of interest Cts that were ≥ 40 or that were undetermined were set to 40 ($n=13$ for colon CYP19A1 analysis, $n=2$ for colon IL6 analysis, $n=86$ for liver CYP19A1 analysis, and $n=9$ for liver IL6 analysis). Two observations were removed from the liver CYP19A1 analysis because the standard deviation among the CYP19A1 triplicates was >1 ; one observation was similarly

removed from the liver IL6 analysis. β -actin was used as the housekeeping gene because it has been shown that structural housekeeping genes such as β -actin have less variation in normal colon and liver tissues than metabolic housekeeping genes such as glyceraldehyde 3-phosphate dehydrogenase.²⁴

SNP genotyping of colon samples

The process of choosing TagSNPs for analysis has been described previously.²² All markers were genotyped using a multiplexed bead array assay format based on GoldenGate chemistry (Illumina, San Diego, CA, USA). A genotyping call rate of 99.93% was achieved. Blinded internal replicates represented 1.6% of the sample set. The duplicate concordance rate was 99.996%. In this study, 25 SNPs from *CYP19A1*, eleven from *NFKB1*, and five from *IL6* were examined.

SNP genotyping of liver samples

Genotyping for SNPs found to be significant in the colon was performed using Taqman SNP Genotyping Assays (Life Technologies, Carlsbad, CA, USA) on the 7900HT Fast Real-Time PCR System (ABI). The PCR protocol was adapted as follows: AmpliTaq activation (95°) for 10 minutes, followed by 50 cycles of denature (95°) for 15 seconds and anneal (58°) for 90 seconds. Samples were automatically called with the post-PCR allelic discrimination protocol, with a genotyping success rate of >95%. One SNP (rs730154) did not have a Taqman primer available, so was not analyzed in liver samples. *CYP19A1* rs17523880 was not in Hardy–Weinberg equilibrium, so was not analyzed either.

Statistical analysis

Effects of individual SNPs on expression

Statistical analyses were performed using SAS version 9.3 software (SAS Institute, Cary, NC, USA). Tests for Hardy–Weinberg equilibrium and linkage disequilibrium measures were calculated and stratified by race using the ALLELE procedure. Median $2^{\Delta\Delta Ct}$ (ΔCt = control Ct – gene of interest Ct)²⁵ values were calculated by genotype initially assuming a codominant model, and the best fitting inheritance model is presented. *P*-values based on nonparametric analysis of variance tests (Wilcoxon rank-sum and Kruskal–Wallis rank-sum tests) were used to detect differences in distribution of expression levels by genotype.

Haplotypes

CYP19A1 SNPs that appeared to be significantly associated (at $\alpha=0.05$) with expression were used to construct haplotypes. Haplotypes were not created based on linkage

disequilibrium bins as tagSNP markers were chosen from different linkage disequilibrium bins. Haplotypes were created based on results from colon samples as follows: all *CYP19A1* SNPs that were significantly associated with *CYP19A1* expression (n=3); all *CYP19A1* SNPs that were significantly associated with *NFKB1* expression (n=4); and all *CYP19A1* SNPs that were significantly associated with *IL6* expression (n=3).

The haplotype reconstruction software, PHASE,²⁶ was used to predict the population frequencies and the “best pair” of haplotypes for each individual. This program provides a “best pair” of haplotypes that most likely explains the genotypes of that subject with the corresponding probability of having that particular haplotype for each individual. If haplotypes for each individual are uncertain, then the program assigns alternative pairs of haplotypes with respective probabilities. PHASE output was read into SAS version 9.3 which created one variable for each haplotype with three possible values, ie, 0 (no copies of that haplotype), 1 (one copy of that haplotype), or 2 (two copies of that haplotype). Association of each haplotype with gene expression was examined again using nonparametric analysis of variance. A *P*-value of less than 0.05 (two-sided) was considered to be statistically significant. Any haplotypes found to be statistically significant in normal colon samples were tested in normal liver samples as well.

Results

Effects of *CYP19A1* SNPs on *CYP19A1* expression

Three *CYP19A1* SNPs were significantly associated with changes in gene expression in colon samples (Table 1). The

Table 1 Association of *CYP19A1* expression and *CYP19A1* SNPs in colon samples

SNPs	Frequency (n)	Median ($2^{\Delta\Delta Ct}$)	Fold change	<i>P</i> -value*
rs10459592				
TT/TG	53	9.95E-05	4.7	0.042
GG	17	4.65E-04		
rs1961177				
CC	51	1.53E-04	1.8	0.040
CT/TT	19	8.37E-05		
rs6493497				
GG	53	1.53E-04	1.9	0.013
GA/AA	17	8.10E-05		

Notes: rs1961177 and rs6493497 $r^2=1$ among Caucasians and 0.58 among African-Americans. *Nonparametric analysis of variance (Kruskal–Wallis or Wilcoxon rank sum test).

Abbreviation: SNPs, single nucleotide polymorphisms.

CYP19A1 rs10459592 homozygous variant genotype (GG) was associated with 4.7-fold higher expression ($P=0.042$) of *CYP19A1* compared with the heterozygous or homozygous common (TT/TG) genotype. The rs1961177 CT/TT genotype was associated with 1.8-fold lower gene expression ($P=0.040$) as compared with the CC genotype. Having one or more copies of the rs6493497 variant allele (GA/AA) was associated with 1.9-fold lower ($P=0.013$) *CYP19A1* expression. No significant associations between *CYP19A1* SNPs and mRNA expression levels were found in the liver samples.

Cross-associations between *CYP19A1* SNPs and *NFκB1* and *IL6* expression in colon samples

The *CYP19A1* rs12908960 homozygous variant genotype (AA) was associated with 2.0-fold lower ($P=0.047$) *NFκB1* expression as compared with the heterozygous or homozygous common (GG/GA) genotype. Having one or more copies of the *CYP19A1* rs730154 or rs8025191 variant allele (AG/GG) was associated with 1.6-fold higher ($P=0.036$) and 1.7-fold lower (although this only approached significance at $P=0.051$) *NFκB1* expression, respectively, as compared with the homozygous common (AA) genotype. Having one or more copies of the *CYP19A1* rs17523880 variant allele (CA/AA) was associated with 1.8-fold lower ($P=0.031$) *NFκB1* expression as compared with the homozygous common (CC) genotype (Table 2, A).

The *CYP19A1* rs11856927 homozygous variant genotype (GG) was associated with 3.1-fold higher ($P=0.049$) *IL6* expression compared with the heterozygous or homozygous common genotype (TT/TG). Having two of the variant alleles in *CYP19A1* rs2470152 (TT) was associated with 3.7-fold higher ($P=0.025$) *IL6* expression compared with the heterozygous or homozygous common genotype (CC/CT), while having one or more of the variant allele in *CYP19A1* rs2470144 (GA/AA) was associated with 3.4-fold higher ($P=0.047$) *IL6* expression (Table 2, B). A summary of P -values for all single nucleotide polymorphisms explored in colon samples can be found in Table S1.

Cross-associations between *CYP19A1* SNPs and *IL6* expression in liver samples

One or two copies of the variant (A) allele of *CYP19A1* rs12908960 or rs2470144 was significantly associated with 3.5-fold and 2.2-fold lower *IL6* expression compared with the homozygous common (GG) genotype ($P=0.004$ and $P=0.022$, respectively, Table 2, C). A summary of P -values

Table 2 Cross-associations of *CYP19A1* genotypes with *IL6* and *NFκB1* gene expression in colon and liver samples

<i>CYP19A1</i> SNPs	Frequency (n)	Median (2 ^{ΔΔCt})	Fold change	P-value*
(A) <i>NFκB1</i> expression in colon				
rs12908960				
GG/GA	65	0.079	2.0	0.047
AA	13	0.040		
rs730154				
AA	39	0.052	1.6	0.036
AG/GG	39	0.085		
rs8025191				
AA	51	0.085	1.7	0.051
AG/GG	27	0.050		
rs17523880				
CC	51	0.082	1.8	0.031
CA/AA	27	0.045		
(B) <i>IL6</i> expression in colon				
rs11856927				
TT/TG	61	0.0031	3.1	0.049
GG	16	0.0094		
rs2470152				
CC/CT	65	0.0033	3.7	0.025
TT	12	0.0121		
rs2470144				
GG	33	0.0023	3.4	0.047
GA/AA	44	0.0079		
(C) <i>IL6</i> expression in liver				
rs12908960				
GG	67	0.0149	3.5	0.004
GA/AA	106	0.0043		
rs2470144				
GG	66	0.0145	2.2	0.022
GA/AA	139	0.0066		

Note: *Nonparametric analysis of variance (Kruskal–Wallis or Wilcoxon rank sums test).

Abbreviations: *IL6*, interleukin-6; SNPs, single nucleotide polymorphisms; *NFκB*, nuclear factor kappa-light-chain-enhancer of activated B-cells.

for all single nucleotide polymorphisms explored in liver samples can be found in Table S2.

Haplotype analysis

The *CYP19A1* rs10459592 T>G, rs1961177 C>T, and rs6493497 G>A haplotype TTA (one copy) was significantly associated with *CYP19A1* expression ($P=0.003$, frequency 0.20; Table 3, A). Haplotype construction of *CYP19A1* rs12908960 G>A, rs730154 A>G, rs17523880 C>A, and rs8025191 A>G demonstrated that two copies of GGCA (frequency 0.12) was associated with increased *NFκB1* expression ($P=0.049$; Table 3, B). A single copy of another *CYP19A1* haplotype (rs11856927 T>G, rs2470152 C>T, rs2470144 G>A) was associated with *IL6* expression (TCG, $P=0.011$, frequency 0.29), with a different combination of GCG approaching significance at $P=0.053$

Table 3 Association of haplotypes of *CYP19A1* SNPs with selected gene expression in colon

<i>CYP19A1</i> SNPs	Frequency	Median (2 ^Δ ΔCt)	SD	P-value*
(A) CYP19A1 expression				
rs10459592 T>G				
rs1961177 C>T				
rs6493497 G>A				
Haplotype				
TTA				
0 copy [†]	0.80	1.8E-4	0.009	0.003
1 copy	0.20	4.8E-5	0.0002	
(B) NFκB1 expression				
rs12908960 G>A				
rs730154 A>G				
rs17523880 C>A				
rs8025191 A>G				
Haplotype				
GGCA				
0 copy	0.51	0.048	0.099	0.049
1 copy	0.37	0.085	0.134	
2 copies	0.12	0.114	0.126	
(C) IL6 expression				
rs11856927 T>G				
rs2470152 C>T				
rs2470144 G>A				
Haplotypes				
TCG				
0 copy	0.71	0.0078	0.151	0.011
1 copy	0.29	0.0019	0.018	
GCG				
0 copy	0.78	0.0047	0.123	0.053
1 copy	0.16	0.0014	0.010	
2 copies	0.06	0.067	0.273	

Notes: Haplotypes created based on results from colon samples; *Nonparametric analysis of variance (Kruskal–Wallis or Wilcoxon rank sum test); [†]0 copy, no copies of the haplotype; 1 copy, one copy of the haplotype; 2 copies, two copies of the haplotype.

Abbreviations: IL6, interleukin-6; SNPs, single nucleotide polymorphisms; NFκB, nuclear factor kappa-light-chain-enhancer of activated B-cells; SD, standard deviation.

(Table 3, C). A summary of haplotype analyses can be found in Table S3.

Discussion

Understanding the interplay between estrogen synthesis genes and inflammatory genes may help to explain the mechanisms behind the role of estrogen in reducing the risk of colon cancer. The estrogen synthesizer CYP19A1 (aromatase, coded by the *CYP19A1* gene), the transcription factor NFκB (coded by *NFκB1*), and the inflammatory cytokine IL6 (coded by *IL6*) may work together to create a feedback loop for homeostasis. An increase in CYP19A1 would lead to an increase in estrogen, which could lead to decreased IL6 production by stabilization of NFκB. The

purpose of this study was to explore the gene expression functionality of, and possible interactions between, SNPs in *CYP19A1* and gene expression of CYP19A1, NFκB1, and IL6 in normal colon samples.

Variants in *CYP19A1* (rs10459592, rs1961177, rs6493497) were significantly associated with CYP19A1 gene expression in colon samples. *CYP19A1* rs1961177 has previously been associated with the risk of colon cancer and rectal cancer.²² Transcription factors and other regulatory molecules vary in expression across organs and tissues, resulting in tissue-specific regulation. Since the liver is the site of first-pass metabolism for many colon carcinogens, genotype–phenotype correlations in DNA and mRNA from 238 normal liver samples were also examined. In contrast with colon tissue, none of the *CYP19A1* SNPs that had a significant association in the colon were significantly associated with CYP19A1 expression in liver samples. The differences seen for *CYP19A1* SNP associations with CYP19A1 gene expression between the organs could be due to differences in expression of transcription factors and regulatory molecules between colon and liver tissues.

When cross-associations were examined in the colon, *CYP19A1* rs12908960, rs730154, rs8025191, and rs17523880 were associated with NFκB1 expression. In addition, *CYP19A1* rs11856927, rs2470152, and rs2470144 were significantly associated with IL6 gene expression. While no single SNP in *CYP19A1* influenced expression in all three genes, these data indicate there may be some cross-talk between genes that affect function. It is possible that the cross-gene associations identified could occur by chance, and rigorous mechanistic testing needs to be performed to verify these observations.

CYP19A1 SNPs found to be significant in the colon were also explored for cross-association in the liver. *CYP19A1* rs12908960 and rs2470144 were associated with IL6 expression in the liver samples. While one or more copies of the variant allele genotype (GA/AA) for rs2470144 were associated with increased expression in colon samples, the variant allele was associated with decreased expression in liver samples. Given this difference in association and the fact that no other cross-associations were found to be significant in the liver, these associations could be organ-specific.

Each of the genes is located on a separate chromosome (*CYP19A1* on 15, *NFκB1* on 4, and *IL6* on 7). Haplotypes were developed with *CYP19A1* SNPs, and expression levels of CYP19A1, NFκB1, and IL6 mRNA were explored in colon samples. Haplotype/activity analysis demonstrated

that haplotype TTA constructed from *CYP19A1* rs10459592 T>G, rs1961177 C>T, and rs6493497 G>A was associated with *CYP19A1* mRNA expression. The *CYP19A1* haplotype GGCA (two copies) constructed from rs12908960 G>A, rs730154 A>G, rs17523880 C>A, and rs8025191 A>G demonstrated a significant influence on expression of NFκB1. The haplotype TCG constructed from *CYP19A1* rs11856927 T>G, rs2470152 C>T, and rs2470144 G>A was associated with *IL6* mRNA expression. The haplotype GCG (constructed from the same SNPs) also showed an association with *IL6* mRNA expression. This association, however, only approached statistical significance ($P=0.053$). These data suggest that *CYP19A1* SNPs, as well as haplotypes, affect NFκB1 and IL6 expression, as well as CYP19A1 expression. The *CYP19A1* haplotype rs12591359, rs17523880, rs1961177, and rs3751591 was reported by Slattery et al to be associated with risk of colon cancer (global $P=0.0059$). This haplotype was tested in normal colon samples in our study, and one construct, ACTT, was significant ($P=0.008$, frequency 0.06). This finding supports the association reported by Slattery et al.²²

Further studies of the coregulation of these genes and their effect on risk of colorectal cancer need to be performed in a large population sample to confirm that these are not false findings based on the small number of colon samples. Samples should also include individuals from different ethnic backgrounds. Other mechanisms also need to be considered, such as the role of transcription factors in these associations. Further study of how NFκB1 may affect the associations shown here is warranted, as well as exploration of other suitable transcription factors. For example, the transcription factor, NF-IL6, has been associated with both CYP19A1²⁷ and (synergistically with NFκB) IL6²⁸ expression in endometrial stromal cells and murine P19 cells, respectively. These associations have not, however, been tested in colon samples. Future studies will include testing this transcription factor at the genetic level, as well as examining the combined effect of these genes and their SNPs on the risk of colon cancer in case-control studies.

These data demonstrate the functional consequences of genetic variation within one gene on interconnected genes within a biologically plausible pathway. They also indicate that there are cross-associations between *CYP19A1* SNPs and NFκB1 and IL6 expression in colon samples, although these findings were not validated in liver samples. Further research may help to elucidate the mechanisms behind the relationships described here. Understanding the estrogen-metabolizing *CYP19A1* gene and its interactions with other pertinent genes

could lead to a better understanding of colon cancer and to more effective prevention and treatment options.

Disclosure

The authors report no conflicts of interest in this work.

References

1. US Cancer Statistics Working Group. United States Cancer Statistics: 1999–2009 incidence and mortality web-based report. 2013. Available from: http://www.cdc.gov/cancer/npcr/pdf/USCS_FactSheet.pdf. Accessed May 5, 2014.
2. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy – long-term follow-up of a Swedish cohort. *Int J Cancer*. 1996;67(3):327–332.
3. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. *J Natl Cancer Inst*. 1995;87(7):517–523.
4. Mahavni V, Sood AK. Hormone replacement therapy and cancer risk. *Curr Opin Oncol*. 2001;13(5):384–389.
5. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. *Obstet Gynecol*. 1999;93(5 Pt 2):880–888.
6. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. *Am J Med*. 1999;106(5):574–582.
7. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. *JAMA*. 2002;288(7):872–881.
8. Harnish DC, Albert LM, Leathurby Y, et al. Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease. *Am J Physiol Gastrointest Liver Physiol*. 2004;286(1):G118–G125.
9. Armstrong CM, Billimek AR, Allred KF, Sturino JM, Weeks BR, Allred CD. A novel shift in estrogen receptor expression occurs as estradiol suppresses inflammation-associated colon tumor formation. *Endocr Relat Cancer*. 2013;20(4):515–525.
10. Ponce C, Torres M, Galleguillos C, et al. Nuclear factor kappaB pathway and interleukin-6 are affected in eutopic endometrium of women with endometriosis. *Reproduction*. 2009;137(4):727–737.
11. Deshpande R, Khalili H, Pergolizzi RG, Michael SD, Chang MD. Estradiol down-regulates LPS-induced cytokine production and NFκB activation in murine macrophages. *Am J Reprod Immunol*. 1997;38(1):46–54.
12. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. *J Surg Oncol*. 2003;83(4):222–226.
13. Fiorelli G, Picariello L, Martinetti V, Tonelli F, Brandi ML. Estrogen synthesis in human colon cancer epithelial cells. *J Steroid Biochem Mol Biol*. 1999;71(5–6):223–230.
14. Sato R, Suzuki T, Katayose Y, et al. Aromatase in colon carcinoma. *Anticancer Res*. 2012;32(8):3069–3075.
15. Cutolo M, Sulli A, Capellino S, et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. *Lupus*. 2004;13(9):635–638.
16. Harle P, Bongartz T, Scholmerich J, Muller-Ladner U, Straub RH. Predictive and potentially predictive factors in early arthritis: a multidisciplinary approach. *Rheumatology (Oxford)*. 2005;44(4):426–433.
17. Xing D, Oparil S, Yu H, et al. Estrogen modulates NFκappaB signaling by enhancing IkappaBalpha levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor-beta. *PLoS One*. 2012;7(6):e36890.
18. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE. Response of tumour cells to hypoxia: role of p53 and NFκB. *Mol Pathol*. 1998;51(2):55–61.

19. Dai Y, Lawrence TS, Xu L. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. *Am J Transl Res*. 2009;1(1):1–15.
20. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. *J Clin Invest*. 2001;107(1):7–11.
21. Curtin K, Wolff RK, Herrick JS, Abo R, Slattery ML. Exploring multilocus associations of inflammation genes and colorectal cancer risk using hapConstructor. *BMC Med Genet*. 2010;11:170.
22. Slattery ML, Lundgreen A, Herrick JS, et al. Variation in the CYP19A1 gene and risk of colon and rectal cancer. *Cancer Causes Control*. 2011;22(7):955–963.
23. Slattery ML, Wolff RK, Herrick JS, Caan BJ, Potter JD. IL6 genotypes and colon and rectal cancer. *Cancer Causes Control*. 2007;18(10):1095–1105.
24. Rubie C, Kempf K, Hans J, et al. Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. *Mol Cell Probes*. 2005;19(2):101–109.
25. Peinnequin A, Mouret C, Birot O, et al. Rat pro-inflammatory cytokine and cytokine related mRNA quantification by real-time polymerase chain reaction using SYBR green. *BMC Immunol*. 2004;5:3.
26. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet*. 2001;68(4):978–989.
27. Yang S, Fang Z, Suzuki T, et al. Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase. *J Clin Endocrinol Metab*. 2002;87(5):2336–2345.
28. Matsusaka T, Fujikawa K, Nishio Y, et al. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. *Proc Natl Acad Sci U S A*. 1993;90(21):10193–10197.

Supplementary materials

Table S1 Association of CYP19A1, NFκB1, and IL6 expression and CYP19A1 SNPs in colon samples

SNPs	Location	CYP19A1 expression P-value	NFκB1 expression P-value	IL6 expression P-value
<i>CYP19A1 (15q21.1)</i>				
rs4275794	51501117	0.42	0.9971	0.0586
rs4646	51502844	0.64	0.6021	0.9072
rs2899472	51516055	0.77	0.5592	0.1061
rs700518	51529112	0.88	0.512	0.2037
rs17703883	51530097	0.39	0.4782	0.914
rs727479	51534547	0.93	0.6143	0.889
rs10459592	51536141	0.04	0.5134	0.1895
rs12591359	51539368	0.31	0.25	0.3854
rs12908960	51545860	0.47	0.0465	0.2858
rs7172156	51546298	0.66	0.17	0.2098
rs11856927	51548705	0.84	0.07	0.0487
rs2414099	51548782	0.68	0.2405	0.7202
rs17601876	51553909	0.82	0.8969	0.0814
rs2470158	51588395	0.99	0.11	0.3283
rs730154	51591204	0.32	0.0363	0.105
rs17523880	51592543	0.13	0.0309	0.9032
rs2470152	51594972	0.38	0.8373	0.0246
rs3751591	51606710	0.61	0.5042	0.687
rs1902584	51611654	0.08	0.7713	0.9128
rs2445762	51617708	0.16	0.07	0.9
rs2470144	51621725	0.39	0.6827	0.047
rs7174997	51622128	0.48	0.2621	0.9908
rs8025191	51623785	0.47	0.0514	0.836
rs1961177	51625078	0.04	0.5676	0.4442
rs6493497	51630835	0.01	0.2108	0.1595

Abbreviations: IL6, interleukin-6; SNPs, single nucleotide polymorphisms; NFκB, nuclear factor kappa-light-chain-enhancer of activated B-cells.

Table S2 Association of CYP19A1, NFκB1, and IL6 expression and CYP19A1 SNPs in liver samples

SNPs	CYP19A1 expression P-value	NFκB1 expression P-value	IL6 expression P-value
<i>CYP19A1</i>			
rs10459592	0.885	0.081	0.088
rs11856927	0.019	0.182	0.374
rs12908960	0.326	0.456	0.004
rs17523880	0.071	<0.001	0.041
rs1902584	0.115	0.554	0.742
rs1961177	0.665	0.329	0.079
rs2470144	0.452	0.593	0.022
rs2470152	0.941	0.646	0.807
rs6493497	0.983	0.11	0.113
rs8025191	0.991	0.5	0.13

Abbreviations: SNPs, single nucleotide polymorphisms; IL6, interleukin-6; NFκB, nuclear factor kappa-light-chain-enhancer of activated B-cells.

Table S3 Association of haplotypes of CYP19A1 SNPs with selected gene expression in colon

CYP19A1 SNPs	Frequency	Median (2 ^{ΔCT})	SD	P-value*
(A) CYP19A1 expression				
rs10459592 T>G				
rs1961177 C>T				
rs6493497 G>A				
Haplotype				
GCG				
0 copy	0.31	0.00120	0.00408	0.38
1 copy	0.50	0.00267	0.01049	
2 copies	0.19	0.00070	0.00091	
TCG				
0 copy	0.40	0.00110	0.00364	0.72
1 copy	0.44	0.00303	0.01111	
2 copies	0.16	0.00040	0.00052	
TTA				
0 copy	0.80	0.00227	0.00863	0.0038
1 copy	0.17	0.00011	0.00019	
2 copies	0.03	0.00031	0.00028	
(B) NFκB1 expression				
rs12908960 G>A				
rs730154 A>G				
rs17523880 C>A				
rs8025191 A>G				
Haplotype				
GGCA				
0 copy	0.51	0.08794	0.09937	0.049
1 copy	0.37	0.12575	0.13461	
2 copies	0.12	0.15026	0.12619	
AACA				
0 copy	0.60	0.09295	0.08635	0.09
1 copy	0.35	0.14648	0.15756	
2 copies	0.05	0.04831	0.05116	
GACA				
0 copy	0.63	0.11540	0.12490	0.79
1 copy	0.34	0.09895	0.10657	
2 copies	0.03	0.09522	0.10883	
AAAG				
0 copy	0.83	0.11841	0.12471	0.22
1 copy	0.15	0.06508	0.05379	
2 copies	0.02	0.03880	0.0001	
AAAA				
0 copy	0.85	0.11301	0.12282	0.84
1 copy	0.15	0.08815	0.08215	

(Continued)

Table S3 (Continued)

CYP19A1 SNPs	Frequency	Median (2 ^{ΔCT})	SD	P-value*
(C) IL6 expression				
rs11856927 T>G				
rs2470152 C>T				
rs2470144 G>A				
Haplotype				
TTG				
0 copy	0.53	0.03375	0.10986	0.98
1 copy	0.43	0.05958	0.15508	
2 copies	0.04	0.05123	0.08554	
TCG				
0 copy	0.71	0.6040	0.15092	0.025
1 copy	0.25	0.00934	0.01893	
2 copies	0.04	0.00138	0.00166	
GCA				
0 copy	0.57	0.04007	0.10889	0.34
1 copy	0.38	0.04857	0.15764	
2 copies	0.05	0.08305	0.14872	
GCG				
0 copy	0.77	0.04360	0.12301	0.053
1 copy	0.16	0.00644	0.00988	
2 copies	0.07	0.16209	0.27339	
TTA				
0 copy	0.81	0.04673	0.13932	0.58
1 copy	0.19	0.04045	0.08229	
TCA				
0 copy	0.92	0.04811	0.13478	0.44
1 copy	0.08	0.01465	0.01784	
GTG				
0 copy	0.92	0.04869	0.13469	0.84
1 copy	0.08	0.00778	0.00644	

Notes: Haplotypes created based on results from colon samples: *non-parametric ANOVA (Kruskal–Wallis or Wilcoxon rank sums test).

Abbreviations: SNPs, single nucleotide polymorphisms; IL6, interleukin-6; NFκB, nuclear factor kappa-light-chain-enhancer of activated B-cells; SD, standard deviation.

Pharmacogenomics and Personalized Medicine

Publish your work in this journal

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. This journal is indexed on the American Chemical

Submit your manuscript here: <http://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal>

Society's Chemical Abstracts Service (CAS). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.